Stoke Therapeutics (STOK) Competitors

NewAmsterdam Pharma (NASDAQ:NAMS) and Stoke Therapeutics (NASDAQ:STOK) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

Does the media refer more to NAMS or STOK?

In the previous week, NewAmsterdam Pharma had 6 more articles in the media than Stoke Therapeutics. MarketBeat recorded 27 mentions for NewAmsterdam Pharma and 21 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 0.61 beat NewAmsterdam Pharma's score of 0.55 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	11 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Stoke Therapeutics	11 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger earnings and valuation, NAMS or STOK?

Stoke Therapeutics has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$47.14M	52.02	-$176.94M	-$1.88	-11.62
Stoke Therapeutics	$190.91M	3.25	-$104.70M	$0.79	14.38

Which has more volatility and risk, NAMS or STOK?

NewAmsterdam Pharma has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.

Is NAMS or STOK more profitable?

NewAmsterdam Pharma has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -629.90%. NewAmsterdam Pharma's return on equity of 0.00% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	N/A	N/A	N/A
Stoke Therapeutics	-629.90%	-54.45%	-40.77%

Do analysts rate NAMS or STOK?

NewAmsterdam Pharma currently has a consensus target price of $43.00, suggesting a potential upside of 96.89%. Stoke Therapeutics has a consensus target price of $23.20, suggesting a potential upside of 104.23%. Given Stoke Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Stoke Therapeutics is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Stoke Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.29

Do insiders & institutionals believe in NAMS or STOK?

89.9% of NewAmsterdam Pharma shares are held by institutional investors. 20.8% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 11.3% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the MarketBeat Community prefer NAMS or STOK?

Stoke Therapeutics received 91 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 90.91% of users gave NewAmsterdam Pharma an outperform vote while only 76.58% of users gave Stoke Therapeutics an outperform vote.

Company	Underperform	Outperform
NewAmsterdam Pharma	Outperform Votes 30 90.91%	Underperform Votes 3 9.09%
Stoke Therapeutics	Outperform Votes 121 76.58%	Underperform Votes 37 23.42%

Summary

Stoke Therapeutics beats NewAmsterdam Pharma on 10 of the 19 factors compared between the two stocks.